Governance and financial results 125 Notes to the Company financial statements 41.
Adoption of new and revised Standards The impact on the company of new and revised standards is the same as for the Group.
Details are given in Note 1 to the consolidated financial statements.
Significant accounting policies The separate financial statements of the Company are presented as required by the Companies Act 2006.
As permitted by that Act, the separate financial statements have been prepared in accordance with International Financial Reporting Standards and UK company law.
The financial statements have been prepared on the historical cost basis.
The principal accounting policies adopted are the same as those set out in Note 2 to the consolidated financial statements with the addition of the policy as noted below.
Investments in subsidiaries are stated at cost less, where appropriate, provisions for impairment.
Investment in subsidiaries Investment in subsidiaries represents the following: Ownership% Ownership% Ordinary Shares Ordinary Shares Companys name Established in 2009 2008 Hikma Pharma Limited Jersey UK 100 100 Hikma Holdings UK Limited UK 100 100 Al Jazeera Pharmaceutical Industries Ltd JPI K. S. A 52.5 52.5 Hikma Pharmaceuticals Limited Jordan 22.8 22.8 The remaining shares are held by other Group companies.
On 23 July 2008 a loan of USD 169,760,000 from the Company to Hikma Pharmacuticals Limited Jordan was converted to equity, giving the Company a 22.8% share.
The investments in subsidiaries are all stated at cost.
Due from subsidiaries As at 31 December 2009 2008 Non-current assets $000s $000s Hikma Investment 8,160 55,459 West-ward Pharmaceuticals Corp 8,424 8,000 Hikma Italia S. p. A 4,420 4,234 Hikma Pharma Limited Jersey 5,674 2,465 26,678 70,158 These balances represent loans that carry interest of 2.2% to 4.8% 2008: 3.9% to 4.8% per annum charged on the outstanding loan balances.
As at 31 December 2009 2008 Current assets $000s $000s Due from Hikma Pharma Limited Jersey 4,431 2,736 Due from Hikma Pharmaceuticals Jordan 97 Due from Hikma Farmaceutica Portugal 445 208 Due from Hikma Pharma Germany 883 587 Due from Hikma UK Limited 96,707 103,544 Due from Hikma Limited 306 429 Others 1,544 782 104,316 108,383 126 Hikma Pharmaceuticals PLC Annual report 2009 Notes to the Company financial statements continued 45.
Financial assets Cash and cash equivalents These comprise cash held by the Company and short-term bank deposits with an original maturity of three months or less.
The carrying amount of these assets approximates to their fair value.
Financial liabilities Other payables The directors consider that the carrying amount of other payables approximates to their fair value.
Short-term debt As at 31 December 2009 there was no outstanding short-term debt.
Short-term debt at 31 December 2008 represents the drawdown of USD 40 million under a USD 60 million credit line.
Due to subsidiaries Due to subsidiaries represents an amount due to Hikma Holdings UK Ltd which is a non interest bearing loan repayable on demand.
Financial policies for risk management and their objectives Currency risk Currency risks as defined by IFRS 7 arise on account of financial instruments being denominated in a currency that is not the functional currency and being of a monetary nature.
The following table illustrates financial assets and liabilities for the Company in different currencies: Liabilities Assets 2009 2008 2009 2008 $000s $000s $000s $000s Euro 87 88 30 162 GBP 788 1,042 183 193 A sensitivity analysis based on a 1% movement in foreign exchange rates has no material impact on the Company results and Company statement of changes in equity.
Further details on how the Company manages the currency risk are given in Note 29 to the Group accounts.
Interest rate risk An interest rate sensitivity analysis assumes an instantaneous 100 basis point change in interest rates in all currencies from their levels at 31 December 2009, with all other variable held constant.
Based on the composition of our debt portfolio as at 31 December 2009, a 1% increase in interest rates would result in no additional interest expense being incurred per year 2008: USD 400,000.
Financial policies for risk management and their objectives continued Liquidity risk: Less than one year Total 2009 $000s $000s Cash and cash equivalents 6,428 6,428 Trade receivables 154 154 Trade payables 292 292 6,290 6,290 Less than one year Total 2008 $000s $000s Cash and cash equivalents 13,176 13,176 Trade receivables 42 42 Interest bearing loans and borrowings 40,000 40,000 Trade payables 201 201 26,983 26,983 The Company believes that given the Groups forecast operating cash flow during 2010, it has the ability to satisfy its liability commitments.
Staff costs Hikma Pharmaceuticals PLC currently has six employees 2008: seven excluding Executive Directors : total compensation paid to them amounted to USD 1,334,000 2008: USD 1,361,000 of which salaries and wages compromise an amount of USD 1,007,000 2008: USD 1,014,000 the remaining balance of USD 327,000 2008: USD 347,000 represent national insurance contributions, the cost of share-based payments and other benefits.
Stock options The details of the stock compensation scheme are provided in Note 36 to the Group accounts.
The number of options granted to the employees of the Company including directors was 2,560,000 2008: 2,600,000 and the total amount of the compensation expenses charged to income statement is USD 194,600 2008: USD 196,400.
Long-Term Incentive Plans LTIPs The details of the LTIP scheme are provided in Note 36 to the Group accounts.
The number of awards granted to the employees of the Company including directors was 656,000 shares 2008: 391,000 and the total amount of the compensation expenses charged to income statement is USD 803,680 2008: USD 513,037.
Share capital 2009 2008 USD 000s USD 000s Authorised: 500,000,000 ordinary shares of 10p each 88,700 88,700 191,627,607 2008: 189,237,607 Ordinary Shares of 10p each 34,236 33,857 The details of the issue of the share capital in the year are given in Note 31 to the Group accounts.
128 Hikma Pharmaceuticals PLC Annual report 2009 Notes to the Company financial statements continued 54.
Share premium Share premium USD 000s Balance at 1 January 2009 977,342 Premium arising on exercise of stock options 2,812 Balance at 31 December 2009 980,154 55.
Net income for the year As permitted by section 408 of the Companies Act 2006, the statement of comprehensive income of the Company is not presented as part of these accounts.
Included in the net income for the year is an amount of USD nil 2008: USD 8,000,000 representing dividends received and USD 998,000 2008: USD 709,000 representing the current year charge of stock option and LTIPs expenses relating to the Companys employees.
The remaining USD 3,618,000 2008: USD 2,675,000 of the Groups stock option and LTIPs charge is recharged to subsidiary companies.
Related party Transactions between the Company and its subsidiaries and associates are disclosed in Note 38.
Amounts repayable to and from subsidiaries are disclosed in Notes 45 and 48.
Other transactions with related parties include management charges for services provided to the subsidiary companies and transactions with key management personnel.
Compensation paid to key management personnel is disclosed at Note 38.
Details of directors remuneration are disclosed in the Remuneration Committee Report on pages 64 to 70.
More details on the general information of the ultimate parent of the Group are disclosed in Note 2.
